News
See also: Aluda Publications
2024
- An invited paper in Cancers by Aluda collaborator Annica Gad at the Karolinksa Institutet is published December 30, 2024. Dr. Gad presents new evidence clarifying vimentin’s role in the EMT as a targetable event The Vimentin-Targeting Drug ALD-R491 Partially Reverts the Epithelial-to-Mesenchymal Transition and Vimentin Interactome of Lung Cancer Cells
- Aluda presents poster on vimentin targeting efficacy in Crohn’s disease at IBD innovate conference in Boston, April 9, 2024. Selected as opportunity of high merit after application for funding. Data shows full resolution of Crohn’s in multiple models, including IL-10 knockout model adapted for higher severity (extended duration increased severity relative to all published data). In this model, shows full resolution of inflammation, tissue damage/ulcers, fibrotic progression, and Disease Activity Index of zero compared to highly severe, fibrotic control animals.
2023
- Aluda presentation at FAST accelerator Showcase, December 11, 2023.
- Dr Ruihuan Chen, CEO and founder of Aluda, makes invited presentation on novel target drug discovery methods at 17th annual Drug Discovery and lead optimization conference, San Fransisco, CA Nov 3, 2023. Topic: Expanding traditional views of precision and targeted drug actions: new frontiers opened by vimentin.
- Aluda selected by California Life Sciences in August 2023 as a top 10 startup, earning spot in the FAST incubator Fall 2023 cohort, from 50+ applicants. Expert advisory team of top executives from biotech and big pharma engaged for 4 month intensive.
2022
- Aluda collaborator Annica Gad published paper on vimentin filament properties and contractile force, further profiling drug actions on vimentin as change in highest dynamic range. Titled ALD-R491 regulates vimentin filament stability and solubility, cell contractile force, cell migration speed and directionality. PMID: 36483676
2021
- Aluda announces third peer-reviewed paper released October 13, 2021 covering further immunological activities in severe models of infection, including in vivo data showing in vivo data on real potential to reduce deaths from immune crisis and ARDS up to 50%. Vimentin’s role in infection is accelerating intake, trafficking and egress of 30+ viruses, plus bacterial and fungal infections, making ALD-R491 one of the broadest pan-pathogen host directed mechansims to date:
-
Aluda announces second peer-reviewed publication on ALD-R491 presenting preclinical data from studies in cancer animal models that show ALD-R491 reduces the elevated levels of exosome released in tumor cell ‘communication’ to normal. Tumor-released Exosomes carry a wide range of cancer signals (checkpoints, to cytokines, primers for metastases and metabolic dysregulation)and enable those signals to ‘hide as self’, and evade drugs and become the basis for resistance. Specific publications by third parties establish that these payloads are responsible for creation and maintenance of the tumor microenvironment (TME), priming other cells for metastases, and imposing metabolic dysregulation.
Related literature from leading cancer centers on tumor-released exosomes and cancer communication: MD Anderson:
- Kalluri, R., LeBleu, V.S. The biology, function, and biomedical applications of exosomes. Science. 2020. PMID: 32029601
- UPenn/MGH: Chen, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 2018 PMID: 30089911
- Aluda releases first peer-reviewed publication on discovery of small molecules showing activity against critical communication processes upregulated in tumor cells. June 28, 2018
2020
- Aluda featured in BioCentury under emerging company profiles. January 20, 2020
Aluda: targeting the fundamentals. Aluda begins to unveil pipeline, starting with first-in-class anti-vimentin program for fibrosis
This document was printed from http://www.aludapharm.com/company/news.html
